Kane Biotech

Kane Biotech Receivables

The Accounts Receivable of Kane Biotech (KNE.V) as of Nov 11, 2026 is 13,700.00 CAD. In the previous year, Accounts Receivable was 3,900.00 CAD — a change of 251.28% (higher).

Receivables

13,700.00CAD

YoY

251.28%

Last updated:

Accounts Receivable of Kane Biotech is 2024 13,700.00 CAD. Accounts Receivable of Kane Biotech was 2023 3,900.00 CAD. It decreases by 251.28% higher compared to the previous year.

The Kane Biotech Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
118,400.00 CAD
Jan 1, 2018
116,300.00 CAD
Jan 1, 2019
361,500.00 CAD
Jan 1, 2020
640,000.00 CAD
Jan 1, 2021
184,200.00 CAD
Jan 1, 2022
321,000.00 CAD
Jan 1, 2023
3,900.00 CAD
Jan 1, 2024
13,700.00 CAD
The Kane Biotech Receivables history
YEARReceivablesYoY
13,700.00CAD+251.28%
3,900.00CAD-98.79%
321,000.00CAD+74.27%
184,200.00CAD-71.22%
640,000.00CAD+77.04%
361,500.00CAD+210.83%
116,300.00CAD-1.77%
118,400.00CAD+64.67%
71,900.00CAD-46.66%
134,800.00CAD+139.86%
56,200.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kane Biotech Stock analysis

What does Kane Biotech do? Kane Biotech, Inc. generates revenue through its portfolio of biotechnology products designed to prevent and remove microbial biofilms. The company commercializes StrixNB, DispersinB, Aledex, bluestem, silkstem, goldstem, coactiv+, and DermaKB Biofilm, with specific focus on the Wound Care & Surgical division developing DispersinB for chronic wound care. The bluestem product line targets animal health markets with water additives, chews, spray, and dental wipes, while Coactiv+ and DispersinB Gel are in development for antimicrobial wound rinse and prosthetic joint infection applications. Additional products include Scalp Detoxifier, Shampoo, and Shampoo Bars for consumer use. Kane Biotech serves animal health markets through its bluestem product line, which includes water additives, chews, spray, and dental wipes. The Wound Care & Surgical division targets medical applications, focusing on DispersinB for chronic wounds and developing Coactiv+ for antimicrobial wound rinse and surgical hydrogel. Consumer products like Scalp Detoxifier, Shampoo, and Shampoo Bars cater to personal care segments. The company's development-stage products such as Coactiv+ antimicrobial surgical hydrogel and DispersinB Gel for prosthetic joint infection represent future revenue streams. The company's primary markets include animal health for bluestem products, medical applications for Wound Care & Surgical division, and consumer personal care for Scalp Detoxifier and Shampoo products. DispersinB is central to the medical division, while bluestem dominates the animal health segment. Development-stage products like Coactiv+ and DispersinB Gel are positioned to address unmet needs in wound care and prosthetic infections, expanding the company's market reach into specialized medical and consumer health segments. Kane Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kane Biotech stock

Accounts Receivable of Kane Biotech is 13,700.00 CAD in 2024.

Accounts Receivable of Kane Biotech changed from 3,900.00 CAD to 13,700.00 CAD, representing a 251.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Kane Biotech since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Kane Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Kane Biotech

All Key Metrics — Kane Biotech